camptothecin has been researched along with ginsenosides in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Feng, YL; Li, B; Ling, CQ; Yu, CQ; Zhu, DZ | 1 |
Calway, T; Du, GJ; Du, W; He, TC; Somogyi, J; Wang, CZ; Wen, XD; Yuan, CS; Zhang, ZY | 1 |
Gu, S; Jin, L; Ma, J; Ni, X; Pan, Q; Wang, J; Xu, M; Zhen, N; Zhu, J | 1 |
1 trial(s) available for camptothecin and ginsenosides
Article | Year |
---|---|
[Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Dexamethasone; Double-Blind Method; Epirubicin; Female; Fluorouracil; Ginsenosides; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Vomiting | 2005 |
2 other study(ies) available for camptothecin and ginsenosides
Article | Year |
---|---|
Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 9; Caspases; Colorectal Neoplasms; Drug Synergism; G1 Phase; Ginsenosides; HCT116 Cells; Humans; Irinotecan; Panax; Phytotherapy; Plant Extracts | 2012 |
Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; DNA Damage; Drug Synergism; Endodeoxyribonucleases; Ginsenosides; Hep G2 Cells; Hepatoblastoma; Humans; Hydroxyurea; Liver Neoplasms; Male; Mice; Mice, Nude; Mitomycin; Nuclear Proteins; Phthalazines; Piperazines; Random Allocation; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2018 |